Short reads

Premium

Merck’s $620 million Rosetta acquisition in May was great fodder for the industry rumor mill. It seems Merck’s CEO Raymond Gilmartin joined Microsoft’s board just two weeks before the acquisition. Meanwhile, Microsoft has been making noise about pursuing pharma industry business. And a member of Rosetta’s board is from Vulcan Ventures, the VC outfit run by Microsoft cofounder Paul Allen. What of this tangled web, you ask?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.